Rapamycin down-regulates LDL-receptor expression independently of SREBP-2

Biochemical and Biophysical Research Communications

Volumn 373, Issue 4, 2008, Pages 670-674

  Sharpe, Laura J ^a   Brown, Andrew J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Hyperlipidemia; LDL receptor; mTOR; Rapamycin; Sirolimus; SREBP 2

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CHOLESTEROL; DACTINOMYCIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MESSENGER RNA; PROTEIN KINASE B; RAPAMYCIN; SOMATOMEDIN C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANIMAL CELL; ARTICLE; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; GENE EXPRESSION REGULATION; HYPERLIPIDEMIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; UPREGULATION;

ANIMALS; CHO CELLS; CHOLESTEROL; CRICETINAE; CRICETULUS; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GOLGI APPARATUS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MEMBRANE PROTEINS; PROTEIN KINASES; RECEPTORS, LDL; RNA STABILITY; SIROLIMUS; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

MAMMALIA;

EID: 48949115069     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.06.108     Document Type: Article

References (23)

1. Goldstein J.L., DeBose-Boyd R.A., and Brown M.S. Protein sensors for membrane sterols. Cell 124 (2006) 35-46
2. Du X.M., Kristiana I., Wong J., and Brown A.J. Involvement of Akt in ER-to-Golgi transport of SCAP/SREBP: a link between a key cell proliferative pathway and membrane synthesis. Mol. Biol. Cell 17 (2006) 2735-2745
3. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
4. Sarbassov D.D., Guertin D.A., Ali S.M., and Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307 (2005) 1098-1101
5. Gao X.S., Zhang Y., Arrazola P., Hino O., Kobayashi T., Yeung R.S., Ru B.G., and Pan D.J. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat. Cell Biol. 4 (2002) 699-704
6. Burnett P.E., Barrow R.K., Cohen N.A., Snyder S.H., and Sabatini D.M. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc. Natl. Acad. Sci. USA 95 (1998) 1432-1437
7. Watson C.J.E., Friend P.J., Jamieson N.V., Frick T.W., Alexander G., Gimson A.E., and Calne R. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 67 (1999) 505-509
8. Wicker L.S., Boltz R.C., Matt V., Nichols E.A., Peterson L.B., and Sigal N.H. Suppression of B-cell activation by cyclosporine-a, Fk506 and rapamycin. Eur. J. Immunol. 20 (1990) 2277-2283
9. Morice M., Serruys P.W., Sousa J.E., Fajadet J., Hayashi E.B., Perin M., Colombo A., Schuler G., Barragan P., Guagliumi G., Molnar F., and Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346 (2002) 1773-1780
10. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., Bruns C.J., Zuelke C., Farkas S., Anthuber M., Jauch K.W., and Geissler E.K. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat. Med. 8 (2002) 128-135
11. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., Leister C., Korth-Bradley J., Hanauske A., and Armand J.P. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J. Clin. Oncol. 22 (2004) 2336-2347
12. Kasiske B.L., de Mattos A., Flechner S.M., Gallon L., Meier-Kriesche H.U., Weir M.R., and Wilkinson A. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am. J. Transpl. 8 (2008) 1-9
13. Liu X.Y., and Zheng X.F.S. Endoplasmic reticulum and golgi localization sequences for mammalian target of rapamycin. Mol. Biol. Cell 18 (2007) 1073-1082
14. Brunn G.J., Williams J., Sabers C., Wiederrecht G., Lawrence J.C., and Abraham R.T. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J. 15 (1996) 5256-5267
15. Kane S., Sano H., Liu S.C.H., Asara J.M., Lane W.S., Garner C.C., and Lienhard G.E. A method to identify serine kinase substrates-Akt phosphorylates a novel adipocyte protein with a Rab GTPase-activating protein (GAP) domain. J. Biol. Chem. 277 (2002) 22115-22118
16. Goldstein J.L., Basu S.K., Brown M.S., Sidney Fleischer F., and Becca. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol. 98 (1983) 241-260
17. Nohturfft A., Yabe D., Goldstein J.L., Brown M.S., and Espenshade P.J. Regulated step in cholesterol feedback localized to budding of SCAP from ER membranes. Cell 102 (2000) 315-323
18. Ma K.L., Ruan X.Z., Powis S.H., Chen Y., Moorhead J.E., and Varghese Z. Sirolimus modifies cholesterol homeostasis in hepatic cells: a potential molecular mechanism for sirolimus-associated dyslipidemia. Transplantation 84 (2007) 1029-1036
19. Ellsworth J.L., Chandrasekaran C., and Cooper A.D. Evidence for sterol-independent regulation of low-density-lipoprotein receptor activity in Hep-G2 cells. Biochem. J. 279 (1991) 175-187
20. Mueller M.A., Beutner F., Teupser D., Ceglarek U., and Thiery J. Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR-/- mice despite severe hypercholesterolemia. Atherosclerosis 198 (2008) 39-48
21. Gueguen Y., Ferrari L., Souidi M., Batt A.M., Lutton C., Siest G., and Visvikis S. Compared effect of immunosuppressive drugs cyclosporine a and rapamycin on cholesterol homeostasis key enzymes CYP27A1 and HMG-CoA reductase. Basic Clin. Pharmacol. Toxicol. 100 (2007) 392-397
22. Grand-Perret T., Bouillot A., Perrot A., Commans S., Walker M., and Issandou M. SCAP ligands are potent new lipid-lowering drugs. Nat. Med. 7 (2001) 1332-1338
23. Grove R.I., Mazzucco C.E., Radka S.F., Shoyab M., and Kiener P.A. Oncostatin-M up-regulates low-density-lipoprotein receptors in Hepg2 cells by a novel mechanism. J. Biol. Chem. 266 (1991) 18194-18199